To prevent muscle loss, more physicians are emphasizing the importance of fat loss vs weight loss for patients taking GLP-1 ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by Fretz et al., ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Opens in a new tab or window The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending ...

Key Takeaways More people with type 1 diabetes are severely obese and using GLP-1 drugs for weight lossExperts are concerned ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.